Recently Viewed

  • Home
  • Stories
  • News Announcement
  • Biocon: Biocon Biologics And Viatris Announce Prime Therapeutics
    Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (Insulin Glargine-Yfgn) Injection And Insulin Glargine (Insulin Glargine-Yfgn) Injection On Its National Formularies
News Announcement

Biocon: Biocon Biologics And Viatris Announce Prime Therapeutics
Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (Insulin Glargine-Yfgn) Injection And Insulin Glargine (Insulin Glargine-Yfgn) Injection On Its National Formularies

04-Nov-2021 Follow Value Research Online on Google download pdfDownload PDF Biocon

Biocon Biologics and Viatris Announce Prime Therapeutics
Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds